
    
      The study was prematurely discontinued on 09Oct2012 due to the tolerability findings in 2
      clinical studies testing PF-04691502 that have prompted the Sponsor to re-evaluate the
      strategic goals of the program. In the study B1271003 an unexpected frequency of severe skin
      toxicity was observed and in the study B1271004 5 cases of drug induced pneumonitis were
      reported.
    
  